Voices

Richard Simcock: Biomarker Testing as Cancer Care’s “Good Problem”

Richard Simcock/LinkedIn

Aug 17, 2025, 14:13

Richard Simcock: Biomarker Testing as Cancer Care’s “Good Problem”

Richard Simcock, Chief Medical Officer at Macmillan Cancer Support, shared Macmillan Cancer Support’s post on LinkedIn, adding:

“The biomarker block is a genuine issue in clinic and part of modern cancer care’s ‘good problem’; increasing precision, new therapies, but extra diagnostic burden.

For people with cancer it’s another delay and distress, “we may or may not have a good new treatment for you but you will have to wait some weeks to find out….”

I look forward to a future where we have rapid access to all relevant testing.”

Quoting Macmillan Cancer Support‘s post :

“Biomarker testing is an exciting advancement in cancer care, but our new research in partnership with AstraZeneca highlights unacceptable inequities in accessing these tests.

We know biomarker testing is a vital step in unlocking potentially life-saving treatments for people with cancer, yet it’s not currently reaching everyone who needs it.

Far too many people are facing barriers to accessing the best possible treatment the UK has to offer and often this can be made worse simply because of who you are or where you live.

But through this research, we’re working to change the narrative. We’re facilitating better access to education and training for healthcare professionals to ensure that every patient gets the information they need to make informed, personalised decisions about their treatment.

We’re working towards a future where biomarker testing is accessible for everyone.

Read more here.”

More posts featuring Richard Simcock on OncoDaily.